



Kuros Biosciences announces treatment of first patient in Australia with MagnetOs for spine fusion

April 8, 2021

- **First patient treated with MagnetOs outside Europe and U.S.**
- **Augmented pricing status is further validation and opportunity for revenue growth.**

Schlieren (Zurich), Switzerland, April 8, 2021 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced the first patient has been treated for spine fusion with MagnetOs bone graft in Australia, the first patient treated outside Europe and the U.S.

The Australian government has granted MagnetOs augmented pricing status on its Prostheses List, under which private health insurers are required to pay a benefit. This reflects the superior efficacy of MagnetOs compared to other synthetic bone grafts and is a result of the strong partnership between Kuros and its Australian distributor, Connexion Surgical, who acquired the rights to distribute MagnetOs from Surgical Specialties as part of a management buy-out at the beginning of 2021.

Joost de Bruijn, Chief Executive Officer of Kuros, said: “We are proud to treat our first patient in Australia with MagnetOs, bringing the benefit of our bone graft to more people around the world. The augmented pricing status of MagnetOs is a further validation of our product, as it requires a substantial demonstration of a novel mechanism of action and efficacy data. This status provides an opportunity for higher revenue and an increased incentive for revenue growth at our partner Connexion Surgical.”

MagnetOs has a unique surface design proven to unlock the untapped power of the body’s immune system, by growing new bone throughout the graft for more predictable fusions. It is supported by a growing set of preclinical data demonstrating equivalence to the current gold standard, autograft, with over three years of clinical experience since its first use in the UK in May 2017.

Dr. John Choi MBChB FRACS (ORTHO), who treated the first 3 patients (1 lumbar and 2 cervical interbody fusions) in Australia with MagnetOs at Peninsula Private Hospital, part of the Ramsay Health hospital group, said: “MagnetOs bone graft provides surgeons like myself a technology that can further help to eliminate non-unions. This ultimately enables my patients to reach their treatment goals and return to living fuller and more active lives after their surgery. These first treatments are a landmark locally and the availability of MagnetOs in Australia will mean more surgeons and patients will benefit from this unique grafting material with the ideal handling properties to support interbody work.”

About MagnetOs bone graft

MagnetOs bone graft has an advanced submicron surface topography that leads to the formation of bone in spinal fusion defects rather than scar tissue. In preclinical models, MagnetOs preferentially directs the body’s early wound healing response toward the bone-forming pathway, an effect that is so potent that bone can be formed even in soft tissues without the need for added cells or growth factors. This ground-breaking research led to Kuros attaining an osteoinductive claim for MagnetOs in Europe. Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. MagnetOs is not cleared by TGA or FDA as an osteoinductive bone graft.

Indications statement

Australia: MagnetOs is intended for use as bone void filler for voids and gaps that are not intrinsic to the stability of the bony structure. MagnetOs is indicated for use in the treatment of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone. MagnetOs is intended to be packed into bony voids or gaps of the skeletal system (i.e., extremities, spine, and pelvis) and may be combined with autologous bone.

All markets: Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions.

About Kuros Biosciences AG

Kuros Biosciences is a leader in next generation bone graft technologies for targeted and controlled bone healing. Kuros’s bone graft substitute, MagnetOs, is commercialized in the U.S. and UK for use in posterolateral spinal fusions. Kuros’s lead product in development, Fibrin PTH, a drug-biologic combination for spinal interbody fusion, has started a phase 2 clinical trial in the U.S. Kuros is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington (MA), U.S. The Company is listed according to the International Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its science and product pipeline.

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

For further information, please contact:

Kuros Biosciences AG	LifeSci Advisors
Michael Grau	Mary-Ann Chang
Chief Financial Officer	Investors
Tel +41 44 733 47 47	+44 7483 284 853
michael.grau@kurosbio.com	mmchang@lifesciadvisors.com